Author:
Zimmer Lisa,Livingstone Elisabeth,Hassel Jessica C,Fluck Michael,Eigentler Thomas,Loquai Carmen,Haferkamp Sebastian,Gutzmer Ralf,Meier Friedegund,Mohr Peter,Hauschild Axel,Schilling Bastian,Menzer Christian,Kieker Felix,Dippel Edgar,Rösch Alexander,Simon Jan-Christoph,Conrad Beate,Körner Silvia,Windemuth-Kieselbach Christine,Schwarz Leonora,Garbe Claus,Becker Jürgen C,Schadendorf Dirk,Berking Carola,Herbst Rudolf A,Martens Uwe M,Sell Sabine,Stadler Rudolf,Terheyden Patrick,Utikal Jochen
Reference32 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol,2018
2. Melanoma;Schadendorf;Lancet,2018
3. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol,2015
4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016
5. Ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial;Eggermont;J Clin Oncol,2019